Talphera advances nafamostat in NEPHRO CRRT; KDIGO update boosts market
Aug 12, 2026, 4:12 PM EDT1 sourcesAI-analyzed
Why it may matterVerify against the original reporting
Positive enrollment progress, KDIGO guideline support, and a larger addressable CRRT market imply potential upside to Nafamostat-related opportunity; however, ongoing losses and cash burn remain risks. Past biotech/med-tech trials with similar milestones have produced sharpism moves when milestones approach and guidelines shift; the key is timing of enrollment completion and regulatory outcomes.
AI summary
What happened, with direct paths to the underlying reporting
Talphera reported Q2 2026 results and updated nafamostat progress in NEPHRO CRRT. With 75% enrollment and a KDIGO guideline recognizing nafamostat as an acceptable CRRT anticoagulant, the company anticipates a larger U.S. market, about 200,000 procedures in 2027 (up 21%). Cash stood at $17.1 million, with an investor event planned as enrollment nears completion.
75% NEPHRO CRRT enrollment; completion expected by year-end 2026.
KDIGO 2026 guideline cites nafamostat as acceptable CRRT anticoagulant.
US CRRT procedures projected at 200,000 in 2027, up 21%.
Nasdaq compliance regained with the $1 bid price rule.
How to read this signal
Transparent limits for an AI-generated research aid
StockNews.AI groups source reporting, classifies the event, and measures subsequent price movement. This is informational research, not investment advice. Prices may be delayed or unavailable.
Related signals
More source-backed signals connected by company or event
